Zoetis Inc. $ZTS Shares Acquired by Associated Banc Corp

Associated Banc Corp increased its stake in Zoetis Inc. (NYSE:ZTS) by 48.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 69,117 shares of the company’s stock after buying an additional 22,493 shares during the quarter. Associated Banc Corp’s holdings in Zoetis were worth $8,696,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis during the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. Finally, Holos Integrated Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 11,650 shares of company stock valued at $886,384 in the last quarter. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Up 1.5%

Shares of Zoetis stock opened at $81.26 on Friday. The business’s fifty day moving average price is $108.11 and its two-hundred day moving average price is $118.65. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market capitalization of $34.06 billion, a P/E ratio of 13.48, a PEG ratio of 1.31 and a beta of 0.87. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.6%. Zoetis’s payout ratio is presently 35.16%.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Finally, Stifel Nicolaus decreased their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.